Update on Pyrin Functions and Mechanisms of Familial Mediterranean Fever

Gayane Manukyan1* and Rustam Aminov2*

1 Group of Molecular and Cellular Immunology, Institute of Molecular Biology, National Academy of Sciences, Yerevan, Armenia, 2 School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK

Mutations in the MEFV gene, which encodes the protein named pyrin (also called meroenostin or TRIM20), are associated with the autoinflammatory disease familial Mediterranean fever (FMF). Recent genetic and immunologic studies uncovered novel functions of pyrin and raised several new questions in relation to FMF pathogenesis. The disease is clinically heterogeneous reflecting the complexity and multiplicity of pyrin functions. The main functions uncovered so far include its involvement in innate immune response such as the inflammasome assemblage and, as a part of the inflammasome, sensing intracellular danger signals, activation of mediators of inflammation, and resolution of inflammation by the autophagy of regulators of innate immunity. Based on these functions, the FMF-associated versions of pyrin confer a heightened sensitivity to a variety of intracellular danger signals and postpone the resolution of innate immune responses. It remains to be demonstrated, however, what kind of selective advantage the heterozygous carriage conferred in the past to be positively selected and maintained in populations from the Mediterranean basin.

Keywords: familial Mediterranean fever, autoinflammation, pyrin, innate immunity, cytoskeleton

INTRODUCTION

Autoinflammatory diseases are a group of genetically determined multisystem disorders caused primarily by the dysfunctions in innate immunity. These rare disorders are characterized by recurrent episodes of generalized inflammation and fever in the absence of infectious or autoimmune causes (McDermott et al., 1999; Brydges and Kastner, 2006). Familial Mediterranean fever (FMF; MIM 294100) is one of the most common and best characterized hereditary autoinflammatory syndromes (Ting et al., 2006; Masters et al., 2009). FMF is an ethnically restricted disease, which predominantly affects people of Mediterranean descent, mainly Armenians, Turks, Arabs and Jews. The carrier rate in these populations is estimated to be as high as 1:5 to 1:7 (Daniels et al., 1995; Gershoni-Baruch et al., 2001; Yilmaz et al., 2001; Sarkisian et al., 2008). Other Mediterranean populations are less affected by the disease, although the number of cases is still substantial (Touitou, 2001; La Regina et al., 2003).

GENETICS OF FMF

Familial Mediterranean fever has long being considered as an autosomal recessive disease caused by mutations in the MEFV gene, which is composed of 10 exons and encodes a 781 amino...
acids protein called pyrin or marenostrin or TRIM20 (The French FMF Consortium, 1997; The International FMF Consortium, 1997). According to the INFEVERS database, more than 60 FMF-associated mutations have been identified so far, with the majority of them being extremely rare mutations (http://fmf.igh.cnrs.fr/infevers/). The FMF-associated mutations are predominantly located within exon 10 of the gene, and they primarily result in amino acid substitutions. The phenotypic variability of the disease is thought to be partially associated with particular mutations and allelic heterogeneity (Dewalle et al., 1998; Shohat et al., 1999). The most frequent mutations causing FMF are the five missense mutations: in exon 10 these are M694V, M694I, V726A, and M680I and in exon 2 – E148Q (Toutou, 2001). Among these five mutations, M694V is associated with a more severe form of the disease (Shinar et al., 2000), and E148Q mutation – with a milder form of the disease (Toutou, 2001).

Despite being long considered as an autosomal recessive disorder, there are some cases with the involvement of only one MEFV heterozygous mutation and even without any apparent MEFV mutation (Booty et al., 2009; Marek-Yagel et al., 2009; Ben-Zvi et al., 2015). Although the genetic defect causing the disease is well-known, a broad spectrum of MEFV-associated phenotypes suggest additional genes or immune factors, which may modulate the innate immune response in FMF. A growing number of studies confirm this hypothesis. It has been suggested that major histocompatibility complex class (HLA) I chain-related gene A has a modifier effect on the disease phenotype (Turkcapan et al., 2007). More recently, differential effects of HLA class I and class II alleles on FMF such as subsets of clinical forms and response to colchicines treatment have been demonstrated for the Japanese population (Yasunami et al., 2015).

The high carrier frequency in affected populations suggests the selective advantage conferred by the heterozygous state such as protection against presumptive pathogen(s). Comparative analyses of amino acid substitutions in the ret finger protein (rfp) domain of pyrin among primates and diseased people have demonstrated that some human mutations actually represent the recapitulation to the ancestral amino acid states and these exist as wild type in other species (Schaner et al., 2001). Inspection of the dN/dS ratios performed by the authors revealed the signature of episodic positive selection. Another study of population genetics of FMF involving the sequence analysis of a larger MEFV region, from exon 5 to the 3′-UTR, essentially supported the hypothesis of heterozygote advantage/overdominance for MEFV mutations (Fumagalli et al., 2009). The meta-analysis of population genetics in FMF suggests that the mutations are not uniformly distributed in various populations and differ in phenotypes, neutrality and other population genetics characteristics (Papadopoulos et al., 2008). The authors identified Jews as the candidate population for founder effects in MEFV mutations due to genetic isolation and genetic drift.

Positive selection to maintain the high frequency of the heterozygotes should be sufficiently strong to overcome the negative effects such as the increased morbidity and mortality rates among the homozygotes and compounded heterozygotes (Twig et al., 2014). There have been suggestions that the mutated forms of the protein may confer an increased protection against tuberculosis (Cattan, 2003) or brucellosis (Ross, 2007) but none had direct evidence provided. Other potential effects of the mutation carrier state are thought may be associated with the protection against asthma (Brenner-Ullman et al., 1994), atopy (Sackesen et al., 2004), or allergy (Kalyoncu et al., 2006). But it is not clear then why this protection mechanism against allergic diseases had not emerged worldwide but remained restricted to the existing geographical and ethnical boundaries.

PYRIN: STRUCTURE AND PROTEIN–PROTEIN INTERACTION

MEFV encodes the protein called pyrin (also known as marenostrin or TRIM20), which is supposed to play a key role in apoptotic and inflammatory signaling pathways. The protein belongs to the large family of proteins sharing a conserved domain structure with the tripartite motif (TRIM) consisting of an N-terminal RING domain, B-box domain(s) and a C-terminal coiled-coil domain (Weinert et al., 2015). In TRIM20 the RING domain with the ubiquitin ligase activity is replaced by the PYD domain, which belongs to the death domain superfamily (Martinon et al., 2001; Gumucio et al., 2002; Kohl and Grüttner, 2004). It also carries an additional ~200-amino acid C-terminal B30.2/rfp/PRY/SPRY domain. The majority of the disease-associated mutations are located in the C-terminal B30.2 domain.

During the last decade the functions of pyrin have been the subject of intensive research, and advances in our understanding of its functionality are the result of identification of its interaction with different proteins and oligomers. In particular, the PYD domain, via cognate pyrin domain association, interacts with an adapter protein denoted apoptosis-associated speck-like protein with a caspase recruitment domain (ASC; Richards et al., 2001), and thus participates in the regulation of apoptosis, inflammation, and IL-1β processing (Gumucio et al., 2002). The B30.2/rfp/PRY/SPRY domain-mediated protein interactions indicate the role of this domain as an adaptor module to assemble macromolecular complexes (Perfetto et al., 2013). As a part of the pyrin inflammasome, pyrin also acts as a pattern recognition receptor sensing pathogen modification and inactivation of Rho GTPases (Xu et al., 2014). Paradoxically, pyrin also acts as a component directing the inflammasome components, NLRP1, NLRP3, and pro-caspase 1, to selective autophagic degradation (Kimura et al., 2015). On its own, the dimerization of B30.2 domains by means of the CHS domain appears to be crucial for the recognition of higher order oligomers (Weinert et al., 2015).

REGULATION OF INNATE IMMUNITY BY PYRIN

Since the positional cloning and characterization of the MEFV gene in 1997 by two consortia (The French FMF Consortium, 1997; The International FMF Consortium, 1997), numerous...
hypotheses have been proposed explaining the potential role of the protein encoded in regulation of innate immune responses. Through N-terminal PYD domain pyrin modulates caspase-1 and IL-1β activation exerting proinflammatory (Yu et al., 2006, 2007; Seshadri et al., 2007; Gavrilon et al., 2012) or anti-inflammatory (Chae et al., 2006; Papin et al., 2007; Hesker et al., 2012) regulatory effects, depending on the experimental system employed. In a number of studies the NALP3 inflammasome complex has been implicated in the pathogenesis of FMF (Papin et al., 2007; Omenetti et al., 2014). More recently, homozygous knock-in mice harboring the mouse pyrin protein fused to the human B30.2 domain containing FMF-associated mutations has been shown to secrete the large amounts of IL-1β in a NLRP3-independent manner (Chae et al., 2011) suggesting the formation of an inflammasome that does not include NLRP3. The pro-inflammatory feature of the pyrin function and the formation of the pyrin inflammasome has been confirmed in several later studies (Gavrilon et al., 2012; Mankan et al., 2012; Xu et al., 2014), which suggested that FMF-associated mutations are gain-of-function for pyrin and pyrin itself promotes ASC oligomerization and forms a caspase-1-activating complex. To add even more to the complexity of functions performed by pyrin, a recent study has established that it is involved in the specific autophagic degradation of cytoplasmic regulators of innate immunity thus contributing to the resolution of inflammatory response (Kimura et al., 2015).

PYRIN AND DANGER SIGNALS

Initially, the similarity of pyrin with other known transcriptional factors has led to speculations that pyrin may itself be a nuclear factor (The International FMF Consortium, 1997; Centola et al., 2000). It has been shown that the protein product of an alternatively spliced mRNA is able to translocate to the nucleus (Papin et al., 2000). The subsequent studies, however, have demonstrated the cytosolic localization of the full-length pyrin. The first evidence for the interaction of the N-terminal part of pyrin with microtubules and co-localization of pyrin with actin has been obtained by Mansfield and co-workers (Mansfield et al., 2001) suggesting that pyrin is a part of unique cytoskeleton signaling pathway. Subsequently, Waite et al. (2009) confirmed this observation by demonstrating the interaction of pyrin, ASC and actin as well as by identifying new interactions of pyrin with the adaptor protein PSTPIP1, which regulates the cytoskeleton and cell migration. Demonstration of the interaction between the B-box/coiled-coil domains of pyrin with PSTPIP1, the protein that is mutated in PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne), confirmed the important role played by pyrin in cytoskeletal signaling pathways (Shoham et al., 2003; Waite et al., 2009). Mutations in PSTPIP1 increase its affinity to pyrin thus suggesting a molecular link between FMF and PAPA syndrome (Shoham et al., 2003).

In a more recent study by Xu et al. (2014) pyrin has been shown to activate caspase-1 in response to Rho GTPases modifying toxins from a number of pathogenic bacteria. They suggested that pyrin recognizes downstream Rho modifications, most likely involving the actin cytoskeleton modifications (Xu et al., 2014). Subsequent studies by Kim et al. (2015) confirmed the link between the aberrant actin depolymerization and inflammasome formation. Moreover, the authors suggested that IL-1β but not IL-1β is implicated in the development of autoinflammatory disease. However, it was shown that pyrin inflammasome is triggered by the lack of actin polymerization using inactivation mutation of the actin-depolymerizing cofactor Wdr1 in mice raised in a gnotobiotic facility (Kim et al., 2015). Thus, the direct participation of pyrin in bacterial sensing has been questioned in this study. Moreover, another interpretation of results by Xu et al. (2014) is that pyrin responds to the modification and inactivation of the host’s proteins by bacterial toxins rather than directly detecting a microbial product (Foley, 2014). In the light of recent findings implicating Rho GTPase in the direct regulation of the pyrin inflammasome the role of the host protein modification as a danger signal is much more prevalent than that of bacterial toxins (Park et al., 2015). Similarly, pertussis toxin with the abolished ADP-ribosyltransferase activity is unable to induce pyrin-dependent inflammasome to cleave pro-IL-1β into the active form (Dumas et al., 2014). Thus the bacterial toxins or components are not the primary danger signals for pyrin inflammasome, there must be modifications of the host proteins in order to be perceived as danger signals.

The relationship between pyrin and cytoskeleton can be additionally confirmed by the therapeutic efficiency of colchicine, an alkaloid with the antimitotic activity, which is recommended and widely used as the first line therapy for the treatment of FMF (Zemer et al., 1986). Moreover, responsiveness to colchicine still has a diagnostic power in FMF. Colchicine exerts various anti-inflammatory effects mostly related to microtubule disruption and depolymerization in a dose-dependent manner (Sackett and Varma, 1993). In a recent study by Taskiran and others the re-organization of actin cytoskeleton in THP-1 cells by colchicine has been described (Taskiran et al., 2012). The mechanisms of its action in FMF have not been completely elucidated and remain under active investigation. It is generally accepted that the therapeutic action of colchicine in FMF is mainly due to the effects on leukocyte migration, signal transduction, and gene expression (Dinarello et al., 1976; Ben-Chetrit et al., 2006; Chae et al., 2008).

Pyrin is primarily expressed in cells of myeloid lineage, mainly polymorphonuclear neutrophils, eosinophils, and monocytes (Centola et al., 2000). Seemingly unprovoked trafficking of these cells to the serosal/synovial membranes is a key event in acute inflammatory attacks of FMF (Ben-Chetrit and Levy, 1998). The regulatory mechanisms implicated in leukocyte migration depend on Ca2+ influx and signaling events that result in changes in cytoskeletal organization, such as assembly and disassembly of F-actin, which provide forces necessary for cell migration (Vicente-Manzanares and Sánchez-Madrid, 2004). The regulation of these activities has recently been shown to involve the Rho family of small GTPases, including Rho, Rac, and Cdc42 (Endlich et al., 2001; Provenzano and Keely, 2011). The
Rho family of GTPases are the key regulators of a variety of cellular activities including motility, proliferation, apoptosis, and, particularly, of actin cytoskeleton rearrangements (Spiering and Hodgson, 2011). It was shown that Rho activation is sufficient to promote migration of monocytes across endothelial cells (Honing et al., 2004). In our experiments, we have observed a phenomenon of heightened sensitivity of neutrophils from FMF patients toward in vitro conditions in the inductor-free media (Manukyan et al., 2013a,b). This suggests that the host-derived stress signals could be responsible for the activation of these cells. Similar results with the use of monocytes have been obtained later by another group (Sugiyma et al., 2014). Experiments in vitro unavoidably impose mechanical forces on cells that may affect cytoskeletal structure and modulate cellular behavior (Wang et al., 1993; Matthews et al., 2006). Thus, the routine experimental procedures involving external mechanical forces applied to cells may lead to the generation of danger signals that are sensed by the pyrin inflammasome. Recent investigations showing the pyrin inflammasome activation in response to actin modifications (Xu et al., 2014; Kim et al., 2015), together with our results suggesting the excessive activation of neutrophils from FMF patients in ex vivo experiments (Manukyan et al., 2013a,b), warrants further studies of pyrin-cytoskeloton interactions, especially in the case of FMF.

**CLINICAL ASPECTS**

Clinically FMF divided into two phenotypes, types 1 and 2 (Shohat and Halpern, 2011). Type 1 is characterized by recurrent episodes of fever and polyserositis. Fever is the main symptom of the disease which is present in 95% of acute inflammation episodes, with the body temperature reaching usually above 38°C (Sohar et al., 1967). Fever is accompanied by sterile peritonitis, synovitis, pleuritis, and rarely by pericarditis and erysipelas-like skin lesions (Shohat and Halpern, 2011). A typical attack lasts 12 h to 2–3 days and resolves spontaneously. The frequency, duration, intensity, and symptoms experienced during attacks are highly variable between patients. During attack-free period patients are asymptomatic. About 50% of the patients are reported to have prodromal symptoms (Lidar et al., 2006). The first clinical presentation of type 2 FMF is amyloidosis, in the absence of other clinical symptoms (Shohat and Halpern, 2011).

The manifestation of the disease is diverse, ranging from asymptomatic to the potentially life-threatening states. The main and potentially lethal complication of the disease is secondary (AA) amyloidosis, which usually affects the kidneys. Amyloidosis is the result of tissue deposition of amyloid, which is a proteolytic cleavage product of the acute phase reactant serum amyloid A (SAA; Sohar et al., 1967). Overproduction of SAA leads to the extracellular accumulation of fibrillar protein and the development of amyloidosis (van der Hilst et al., 2005). Presently the administration of colchicine (1–3 mg/day) is the preferred treatment for FMF allowing extended periods of remission as well as preventing amyloidosis in the majority of FMF patients (Pras, 1998). Since 5–10% of the patients are colchicine resistant or intolerant to the drug, the efforts toward developing alternative treatment were undertaken. As an alternative approach, specific anti-cytokine therapies, such as IL-1 receptor and tumor necrosis factor antagonists were tested with a limited number of patients (Nakamura et al., 2007; Ben-Zvi and Livneh, 2014). Although, genotyping of the MEFV mutations is the preferred method in FMF diagnostics, it is confirmatory to the clinical diagnosis. Presently, there are no definitive biochemical markers that could serve as diagnostic ones. Usually FMF attacks are accompanied by a non-specific increase in acute phase reactants such as C-reactive protein, fibrinogen, and serum amyloid A as well as by the increased white blood cell count with low-grade neutrophilia. The diagnosis of FMF remains clinical, since mutations have reduced penetrance and cannot always be identified on both alleles (Tunca et al., 2002). Clinical manifestations of FMF may overlap with the phenotypes of autoinflammatory disorders and, to a certain degree, with autoimmune diseases, which may potentially complicate diagnosis of FMF. One distinguishing feature of autoinflammatory syndroms is responsiveness to IL-1β blocking therapy, although there are exceptions (Bodar et al., 2005; Arostegui et al., 2007; Kuijk et al., 2007; Gattorno et al., 2008).

Several studies have demonstrated association of MEFV mutations with different inflammatory pathologies, such as systemic onset juvenile idiopathic arthritis (Uslu et al., 2010), inflammatory bowel disease (Akyuz et al., 2013), Behçet’s disease (Atagunduz et al., 2003), ulcerative colitis (Giaglis et al., 2006), Fibromyalgia syndrome (Feng et al., 2009), rheumatoid arthritis (Rabinovich et al., 2005), ankylosing spondylitis (Akkoc et al., 2010), and others. Other pathologies, which are associated with mutations in the MEFV gene, are two vasculitis types, Henoch-Schonlein Purpura (Gershoni-Baruch et al., 2003; Tunca et al., 2005) and polyarteritis nodosa (Tunca et al., 2005; Aksu and Keser, 2011). Clinical manifestations of these vasculitis types, which accompany FMF, might be considered as a clinical manifestation of the latter. The diseases listed represent multifactorial immunological disorders with a marked involvement of the inflammatory component. A growing number of similar cases, which are reported to be associated with the MEFV gene,

**TABLE 1 | Structural and functional roles of pyrin in cellular processes.**

| Role                                      | Reference                                      |
|-------------------------------------------|------------------------------------------------|
| Inflammasome assembly                      | Chae et al., 2011; Perfetto et al., 2013;      |
|                                           | Vajhala et al., 2014                           |
| Sensing intracellular danger signals by   | Dumas et al., 2014; Xu et al., 2014; Kim et al.,|
| the inflammasome (aberrant actin          | 2015                                           |
| depolymerisation, protein modification by  |                                                |
| bacterial toxins)                         |                                                |
| Activation of mediators of inflammation   | Chae et al., 2011; Kim et al., 2015            |
| by the inflammasome (IL-1ß, IL-18)        |                                                |
| Pyrin-cytoskeloton interactions          | Mansfield et al., 2001; Shoham et al., 2003;   |
|                                           | Waite et al., 2009                            |
| Apoptosis                                 | Martinon et al., 2001; Richards et al., 2001;  |
|                                           | Gumucio et al., 2002                          |
| Autophagy of innate immunity regulators   | Mandell et al., 2014; Kimura et al., 2015      |
suggest that pyrin is a key regulatory element of the innate immune responses and can affect inflammatory processes during these disorders.

**CONCLUDING REMARKS**

Understanding the role of pyrin in innate immunity has progressed rapidly in recent years, uncovering its numerous functions in the cell from the formation of several supramolecular structures and inflammasome assembly, to sensing various intracellular danger signals, to mounting the innate immune responses, and to the resolution of inflammation (Table 1). The evidences for positive selection of mutations in the MEFV gene are given in several works cited in this review, and they have a strong support from the formal analytical approaches of population genetics. What remains unclear, however, why the mutations have been selected and maintained in the Mediterranean populations and what are the mechanistic explanations for the advantage at the biochemical level? In particular, we know well about the negative effects of the homozygous or compounded heterozygous mutant allele combination, which result in a higher morbidity/mortality rate. At the cellular level this genetics presumably results in the impaired assembly of pyrin inflammasomes, in the launch of excessive and extended inflammatory responses, and in a less efficient resolution of inflammation. Given the multiple functions of pyrin and the expected pleiotropic effects of mutations in the MEFV gene, the significance and contribution of each of these functions are difficult to ascertain in terms of clinical presentation in pathology or the heterozygote advantage at the phenotypic level. All we know at the clinical level is that the homozygous or compounded heterozygous state results in the enhanced and extended inflammatory response to some of the innocuous factors that are tolerated well and handled efficiently by the normal immune system. The diseased state is certainly disadvantageous (although it cannot be excluded that certain conditions in the past have been conducive to select such traits) but we don’t know about the possible advantages conferred by the heterozygote state. Investigation of this previously ignored group could potentially reveal the characteristics and traits that were responsible for the selective advantage and maintenance of these mutations in the Mediterranean populations.

**REFERENCES**

Akkoc, N., Sari, I., Akar, S., Rinicier, O., Thomas, M. G., Weale, M. E., et al. (2010). Increased prevalence of M694V in patients with ankylosing spondylitis: additional evidence for a link with familial Mediterranean fever. *Arthritis Rheum.* 62, 3059–3063. doi: 10.1002/art.27598

Aksu, K., and Keser, G. (2011). Coexistence of vasculitides with familial Mediterranean fever. *Rheumatol. Int.* 31, 1263–1274. doi: 10.1007/s00296-011-1840-z

Akyuz, F., Besisik, F., Ustek, D., Ekmekci, C., Uyar, A., Pinarbasi, B., et al. (2013). Association of the MEFV gene variations with inflammatory bowel disease in Turkey. *J. Clin. Gastroenterol.* 47, e23–e27. doi: 10.1097/MCG.0b013e3182597992

Arostegui, J. I., Armal, C., Merino, R., Modesto, C., Antonia, C. M., Moreno, P., et al. (2007). NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. *Arthritis Rheum.* 56, 3805–3813. doi: 10.1002/art.22966

Atagunduz, P., Ergun, T., and Direskeneli, H. (2003). MEFV mutations are aakyung to the Akyuz, F., Besisik, F., Ustek, D., Ekmekci, C., Uyar, A., Pinarbasi, B., et al. (2013). Association of the MEFV gene variations with inflammatory bowel disease in Turkey. *J. Clin. Gastroenterol.* 47, e23–e27. doi: 10.1097/MCG.0b013e3182597992

Arostegui, J. I., Armal, C., Merino, R., Modesto, C., Antonia, C. M., Moreno, P., et al. (2007). NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. *Arthritis Rheum.* 56, 3805–3813. doi: 10.1002/art.22966

Atagunduz, P., Ergun, T., and Direskeneli, H. (2003). MEFV mutations are increased in Behjét’s disease (BD) and are associated with vascular involvement. *Clin. Exp. Rheumatol.* 21(4 Suppl. 30), S35–S37.

Ben-Chetrit, E., Bergmann, S., and Sood, R. (2006). Mechanism of the anti-inflammatory effect of colchicine in rheumatic diseases: a possible new outlook through microarray analysis. *Rheumatology* (Oxford) 45, 274–282. doi: 10.1093/rheumatology/kei140

Ben-Chetrit, E., and Levy, M. (1998). Familial Mediterranean fever. *Lancet* 351, 659–664. doi: 10.1016/S0140-6736(97)90408-7

Ben-Zvi, I., Herskovizh, C., Kukuy, O., Kassel, Y., Grossman, C., and Livneh, A. (2015). Familial Mediterranean fever without MEFV mutations: a case-control study. *Orphanet J. Rare Dis.* 10, 34. doi: 10.1186/s13023-015-0252-7

Ben-Zvi, I., and Livneh, A. (2014). Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. *Isr. Med. Assoc. J.* 16, 271–273.

Bodar, E. J., van der Hilst, J. C., Drenth, J. P., van der Meer, J. W., and Simon, A. (2005). Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. *Neth. J. Med.* 65, 260–264.

Booty, M. G., Chae, J. J., Masters, S. L., Remmers, E. F., Barham, B., Le, J. M., et al. (2009). Familial Mediterranean fever with a single MEFV mutation: where is the second hit? *Arthritis Rheum.* 60, 1851–1861. doi: 10.1002/art.24569

Brenner-Ullman, A., Melzer-Ofir, H., Daniels, M., and Shohat, M. (1994). Possible protection against asthma in heterozygotes for familial Mediterranean fever. *Am. J. Med. Genet.* 2, 172–175. doi: 10.1002/ajmg.1320530210

Brydges, S., and Kastner, D. L. (2006). The systemic autoinflammatory diseases: inborn errors of the innate immune system. *Curr. Top. Microbiol. Immunol.* 305, 127–160.

Cattan, D. (2008). Familial Mediterranean fever: is low mortality from tuberculosis a specific advantage for MEFV mutations carriers? Mortality from tuberculosis among Muslims, French, Italian and Maltese patients in StateTunis (Tunisia) in the first half of the 20th century. *Clin. Exp. Rheumatol.* 4(Suppl. 30), S53–S54.

Centola, M., Wood, G., Frucht, D. M., Galon, J., Aringer, M., Farrell, C., et al. (2000). The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. *Blood* 95, 3223–3231.

Chae, J. J., Cho, Y. H., Lee, G. S., Cheng, J., Liu, P. P., Feigenbaum, L., et al. (2011). Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. *Immunity* 34, 755–768. doi: 10.1016/j.immuni.2011.02.020

Chae, J. J., Wood, G., Masters, S. L., Richard, K., Park, G., Smith, B. J., et al. (2006). The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1βeta production. *Proc. Natl. Acad. Sci. U.S.A.* 103, 9982–9987. doi: 10.1073/pnas.0602081103

Chae, J. J., Wood, G., Richard, K., Jaffe, H., Colburn, N. T., Masters, S. L., et al. (2008). The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. *Blood* 112, 1794–1803. doi: 10.1182/blood-2008-01-134932

Daniels, M., Shohat, T., Brenner-Ullman, A., and Shohat, M. (1995). Familial Mediterranean fever: high gene frequency among the non-Ashkenazi and
Ashkenazi Jewish populations in Israel. Am. J. Med. Genet. 55, 311–314. doi: 10.1002/ajmg.1320550313

Dewalle, M., Domingo, C., Rozenbaum, M., Ben-Chetrit, E., Cattan, D., Bernot, A., et al. (1998). Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF). Eur. J. Hum. Genet. 6, 95–97. doi: 10.1038/sj.ejhg.5200170

Dinarello, C. A., Chusid, M. J., Fauci, A. S., Gallin, J. L., Dale, D. C., and Wolff, S. M. (1976). Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum. 19, 618–622. doi: 10.1002/art.1780190315

Dumas, A., Amiable, N., de Rivero Vaccari, J. P., Chae, J. J., Keane, R. W., Lacroix, S., et al. (2012). The inflammasome pyrin contributes to pertussis toxin-induced IL-1β synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis. PLoS Pathog. 10:e1004150. doi: 10.1371/journal.ppat.1004150

Endlich, N., Kress, K. R., Reiser, J., Uutenweiler, D., Kriz, W., Mundel, P., et al. (2001). Podocytes respond to mechanical stress in vitro. J. Am. Soc. Nephrol. 12, 413–422.

Feng, J., Zhang, Z., Li, W., Shen, X., Song, W., Yang, C., et al. (2009). Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. PLoS ONE 4:e8480. doi: 10.1371/journal.pone.0008480

Foley, J. F. (2014). Detecting a pathogenic activity, not a pathogenic molecule. Sci. Signal. 7:ecs252. doi: 10.1126/scisignal.2003897

Fumagalli, M., Caglioni, R., Pozzoli, V., Riva, S., Comi, G. P., Menozzi, G., et al. (2007). A population genetics study of the familial Mediterranean fever gene: evidence of balancing selection under an overdominance regime. Genes Immun. 10, 678–686. doi: 10.1046/j.1365-2918.2006.00959.x

Gattorno, M., Pelagatti, M. A., Meini, A., Obici, L., Barcellona, R., Federici, S., et al. (2008). Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58, 1516–1520. doi: 10.1002/art.23475

Gavrila, M. A., Abdelaziz, D. H., Mostafa, M., Abdulrahman, B. A., Grandhi, J., et al. (2006). Familial Mediterranean fever is no longer a rare disease in Italy. Eur. J. Hum. Genet. 11, 50–56. doi: 10.1038/sj.ejhg.5200916

Manukyan, G., Petrek, M., Kriegova, E., Ghazaryan, K., Fillerova, R., and Boyajian, A. (2013a). Activated phenotype of circulating neutrophils in familial Mediterranean fever. Immunobiology 218, 892–898. doi: 10.1016/j.imbio.2012.10.007

Manukyan, G., Petrek, M., Tomkova, T., Martirosyan, A., Tatyam, M., Navratilova, Z., et al. (2013b). Colchicine modulates expression of pro-inflammatory genes in neutrophils from patients with familial Mediterranean fever and healthy subjects. J. Biol. Regul. Homeost. Agents 27, 329–336.

Merek-Yagel, D., Berkun, Y., Padeh, S., Abu, A., Renzik-Wolf, H., Livneh, A., et al. (2009). Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 60, 1862–1866. doi: 10.1002/art.24570

Martinon, F., Hofmann, K., and Tschopp, J. (2001). The pyrin domain: a receptor associated with microtubules and colocalizes with actin filaments. Dev. Cell 10, 369–377. doi: 10.1016/S1534-5807(01)00056-2

Mikkelsen, S. L., Simon, A., Akkentievich, L., and Kastner, D. L. (2009). Horrorn autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621–628. doi: 10.1146/annurev.immunol.25.022106.141627

Matthews, B. D., Overby, D. R., Mannix, R., and Ingber, D. E. (2006). Cellular adaptation to mechanical stress: role of integrins, Rho, cytokeskeletal tension and mechanosensitive ion channels. J. Cell Sci. 119, 508–518. doi: 10.1242/jcs.02760

McDermott, M. F., Akkentievich, I., Galon, J., McDermott, E. M., Ogunkolade, B. W., Centola, M., et al. (1999). Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97, 133–144. doi: 10.1016/S0092-8674(00)00721-7

Nakamura, A., Matsuda, M., Tazawa, K., Shimojima, Y., and Ikeda, S. (2007). Successful treatment with infliximab and low-dose methotrexate in a Japanese patient with familial Mediterranean fever. Int. Med. 46, 1247–1249. doi: 10.2169/internalmedicine.46.0064

Omenetti, A., Carta, S., Delfino, L., Martini, A., Gattorno, M., and Rubartelli, A. (2014). Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann. Rheum. Dis. 73, 462–469. doi: 10.1136/annrheumdis-2012-202774

Papadopoulos, V. P., Giaglis, S., Mitroulis, I., and Ritis, K. (2008). The population genetics of familial Mediterranean fever: a meta-analysis study. Ann. Hum. Genet. 72, 752–761. doi: 10.1111/j.1469-1809.2008.00471.x
Spiering, D., and Hodgson, L. (2011). Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh. Migr. 5, 170–180. doi: 10.4161/cam.5.2.14403

Sugiyama, R., Agematsu, K., Migita, K., Nakayama, J., Mokuda, S., Ogura, F., et al. (2014). Defect of suppression of inflammasome-independent interleukin-8 secretion from SW982 synovial sarcoma cells by familial Mediterranean fever-derived pyrin mutations. Mol. Biol. Rep. 41, 545–553. doi: 10.1007/s11033-013-2840-y

Taskiran, E. Z., Cetinkaya, A., Balci-Peynirciglu, B., Akkaya, Y. Z., and Yilmaz, E. (2012). The effect of colchicine on pyrin and pyrin interacting proteins. J. Cell Biochem. 113, 3536–3546. doi: 10.1002/jcb.24231

The French FMF Consortium (1997). A candidate gene for familial Mediterranean fever. Nat. Genet. 17, 25–31. doi: 10.1038/ng0997-25

The International FMF Consortium (1997). Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90, 797–807. doi: 10.1016/S0092-8674(00)80539-5

Ting, J. P., Kastner, D. L., and Hoffman, H. M. (2006). CATERPILLERS, pyrin and hereditary inflammatory disorders. Nat. Rev. Immunol. 6, 183–195. doi: 10.1038/nri1788

Touitou, I. (2001). The spectrum of familial Mediterranean fever (FMF) mutations. Eur. J. Hum. Genet. 9, 473–483. doi: 10.1038/sj.ejhg.5200658

Tunca, M., Akar, S., Hawkins, P. N., Booth, S. E., Sengül, B., Yavuzcu, T. U., et al. (2002). The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. Eur. J. Hum. Genet. 10, 786–789. doi: 10.1038/sj.ejhg.5200900

Tunca, M., Akar, S., Onen, F., Ozdogan, H., Kasapcopur, O., Yalcinkaya, F., et al. (2005). Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 84, 1–11. doi: 10.1097/01.ard.0000152370.84628.0c

Turkcapar, N., Tuncali, T., Kutlay, S., Burhan, B. Y., Kinikli, G., Erturk, S., et al. (2007). The contribution of genotypes at the MICA gene triplet repeat polymorphisms and MEFV mutations to amyloidosis and course of the disease in the patients with familial Mediterranean fever. Rheumatol. Int. 27, 545–551. doi: 10.1007/s00296-006-0255-8

Tugrul, G., Livneh, A., Vivante, A., Afek, A., Shamiss, A., Derazne, E., et al. (2014). Mortality risk factors associated with familial Mediterranean fever among a cohort of 1.25 million adolescents. Ann. Rheum. Dis. 73, 704–709. doi: 10.1136/annrheumdis-2012-202932

Uslu, N., Yuçe, A., Demir, H., Saltık-Temizel, I. N., Usta, Y., Yılmaz, E., et al. (2010). The association of inflammatory bowel disease and Mediterranean fever gene (MEFV) mutations in Turkish children. Dig. Dis. Sci. 55, 3488–3494. doi: 10.1007/s10620-010-1178-5

Vajjhala, P. R., Kaiser, S., Smith, S. J., Ong, Q. R., Soh, S. L., Stacey, K. J., et al. (2014). Identification of multifaceted binding modes for pyrin and ASC pyrin domains gives insights into pyrin inflammasome assembly. J. Biol. Chem. 289, 23504–23519. doi: 10.1074/jbc.M114.553305

van der Hilst, J. C., Simon, A., and Drenth, J. P. (2005). Hereditary periodic fever in the absence of MEFV mutations. Clin. Exp. Med. 5, 87–98. doi: 10.1007/s10238-005-0071-6

Vicente-Manzanares, M., and Sánchez-Madrid, F. (2004). Role of the cytoskeleton during leucocyte responses. Nat. Rev. Immunol. 4, 110–122. doi: 10.1038/nri1268

Waite, A. L., Schaner, P., Hu, C., Richards, N., Balci-Peynirciglu, B., Hong, A., et al. (2009). Pyrin and ASC co-localize to cellular sites that are rich in polymerizing actin. Exp. Biol. Med. (Maywood) 234, 40–52. doi: 10.3810/0806-196-184

Wang, N., Butler, J. P., and Ingber, D. E. (1993). Mechanotransduction across the cell surface and through the cytoskeleton. Science 260, 1124–1127. doi: 10.1126/science.7684161

Weinert, C., Morger, D., Djekic, A., Grütter, M. G., and Mittl, P. R. (2015). Crystal structure of TRIM20 C-terminal coiled-coil/B30.2 fragment: implications for the recognition of higher order oligomers. Sci. Rep. 5, 10819. doi: 10.1038/srep10819

Xu, H., Yang, J., Gao, W., Li, L., Li, P., Zhang, L., et al. (2014). Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513, 237–241. doi: 10.1038/nature13449

Yamanaka, M., Nakamura, H., Agematsu, K., Nakamura, A., Yasaki, M., Kubida, D., et al. (2015). Identification of disease-promoting HLA class I and protective class II modifiers in Japanese patients with familial Mediterranean fever. PLoS ONE 10:e0125938. doi: 10.1371/journal.pone.0125938
Yilmaz, E., Ozen, S., Balci, B., Duzova, A., Topaloglu, R., Besbas, N., et al. (2001). Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. *Eur. J. Hum. Genet.* 9, 553–555. doi: 10.1038/sj.ejhg.5200674

Yu, J. W., Fernandes-Alnemri, T., Datta, P., Wu, J., Juliana, C., Solorzano, L., et al. (2007). Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. *Mol. Cell* 28, 214–227. doi: 10.1016/j.molcel.2007.08.029

Yu, J. W., Wu, J., Zhang, Z., Datta, P., Ibrahim, I., Taniguchi, S., et al. (2006). Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. *Cell Death. Dif.* 13, 236–249. doi: 10.1038/sj.cdd.4401734

Zemer, D., Pras, M., Sohar, E., Modan, M., Cabili, S., and Gafni, J. (1986). Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. *N. Engl. J. Med.* 314, 1001–1005. doi: 10.1056/NEJM198604173141601

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Manukyan and Aminov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.